Skip to main content
. 2023 Feb 24;9(3):e13763. doi: 10.1016/j.heliyon.2023.e13763

Table 5.

EBGM scores and corresponding 95% CIs for preferred terms from MedDRA

EBGM
EB05 EBGM
EB05 EBGM
EB05 EBGM
EB05 EBGM
EB05 EBGM
EB05
Apixaban Dabigatran Edoxaban Heparin Rivaroxaban Warfarin
Bronchitis 1.68 1.37 1.13 0.78 1.13 0.55 0.84 0.6 0.46 0.37 1.71 1.45
Cough 1.75 1.56 0.69 0.52 1.85 1.27 0.6 0.48 0.56 0.5 1.58 1.43
Dysphonia 1.67 1.3 0.29 0.1 0.69 0.23 0.52 0.31 0.49 0.38 1.99 1.65
Dyspnoea 1.31 1.22 0.92 0.81 1.49 1.17 1.3 1.19 0.61 0.57 1.41 1.34
Emphysema 1.52 0.94 NA NA NA NA 0.97 0.5 0.49 0.29 1.65 1.12
Nasopharyngitis 1.61 1.34 0.58 0.37 0.62 0.25 0.28 0.17 0.58 0.48 1.87 1.63
Oropharyngeal pain 1.4 1.1 0.77 0.47 1.5 0.76 0.52 0.33 0.54 0.43 1.98 1.68
Pleural effusion 1.04 0.86 1.29 1 0.61 0.27 1.95 1.66 0.53 0.46 1.34 1.17
Pleurisy 0.58 0.23 0.95 0.38 1.18 0.4 1.05 0.51 0.68 0.4 1.64 1.04
Pneumonia 1.32 1.2 1 0.84 1.52 1.1 1.6 1.44 0.59 0.54 1.32 1.22
Pneumonia aspiration 0.95 0.68 1.01 0.62 2.72 1.44 1.57 1.17 0.63 0.5 1.25 0.99
Pulmonary edema 1.15 0.9 0.62 0.37 0.77 0.31 2.61 2.15 0.46 0.36 1.31 1.08
Sinusitis 1.45 1.1 0.78 0.45 0.68 0.22 0.46 0.26 0.57 0.44 1.85 1.53